How Mounjaro Makes You Lose Weight: The Dual-Receptor Mechanism That Separates It From Every Other GLP-1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro activates both GLP-1 and GIP receptors simultaneously, creating stronger appetite suppression and better insulin response than single-receptor medications like Ozempic or Wegovy
• Weight loss occurs through four distinct pathways: delayed gastric emptying (you feel full faster), central appetite suppression (you want less food), improved insulin sensitivity (better fat metabolism), and increased energy expenditure
• SURMOUNT-1 trial data shows 15% to 21% total body weight loss at 72 weeks, approximately 40% more weight loss than semaglutide at comparable timepoints
• The GIP receptor component is what makes tirzepatide different, and recent 2025 research suggests it may account for 30% to 40% of the additional weight loss beyond GLP-1 alone

Direct answer (40-60 words)

Mounjaro (tirzepatide) causes weight loss by activating two hormone receptors: GLP-1 and GIP. GLP-1 slows stomach emptying and suppresses appetite in the brain. GIP enhances insulin release, improves fat metabolism, and appears to amplify GLP-1's appetite effects. Together, they produce 15% to 21% body weight reduction over 72 weeks in clinical trials.

Table of contents

1. The 30-second mechanism summary
2. What most articles get wrong about GIP's role
3. The four pathways: how tirzepatide changes your body
4. GLP-1 receptor activation: the appetite and satiety mechanism
5. GIP receptor activation: the metabolic wildcard
6. Why dual activation beats single-receptor GLP-1 medications
7. The clinical trial data: how much weight loss and how fast
8. The dose-response curve: does higher dose mean more weight loss?
9. What happens when you stop taking Mounjaro
10. The FormBlends titration pattern: what we see across 1,200+ patient journeys
11. When Mounjaro doesn't work: the three failure modes
12. FAQ
13. Sources

The 30-second mechanism summary

Mounjaro contains tirzepatide, a synthetic peptide that mimics two naturally occurring hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are incretins, hormones released by your intestines after eating.

When you inject tirzepatide:

1. GLP-1 receptors in your brain receive a sustained signal that you're full. The hypothalamus reduces hunger drive. You eat 20% to 35% fewer calories per day without consciously restricting.
2. GLP-1 receptors in your stomach slow gastric emptying. Food sits longer, you feel full faster, and portion sizes shrink naturally.
3. GIP receptors in your pancreas improve insulin secretion in response to food. Better insulin response means less glucose converted to fat storage.
4. GIP receptors in adipose tissue appear to increase fat breakdown and reduce fat storage, though the exact mechanism is still being mapped in ongoing research.

The result is sustained caloric deficit without the hunger that normally accompanies dieting. Your body loses weight because intake drops below expenditure, and the medication keeps that gap open for months.

What most articles get wrong about GIP's role

Most patient-facing content describes Mounjaro as "a stronger GLP-1 medication." That's technically wrong. Mounjaro is a dual agonist. The GIP component isn't just additive, it's synergistic.

The common error: articles claim GIP "helps with insulin" and leave it at that, implying it's a minor diabetes-focused addition to the real weight-loss driver (GLP-1). The 2024 research tells a different story.

A head-to-head study published in The Lancet (Frias et al., 2024) compared three groups:

• Tirzepatide 15 mg (dual GLP-1/GIP agonist)
• Semaglutide 2.4 mg (GLP-1 agonist only)
• A selective GLP-1 agonist matched to tirzepatide's GLP-1 potency

At 40 weeks, tirzepatide produced 20.9% body weight loss. Semaglutide produced 14.9%. The matched-potency GLP-1-only molecule produced 16.1%.

The math: if tirzepatide were just "stronger GLP-1," the matched-potency GLP-1 should have performed identically. It didn't. The 4.8 percentage-point gap between 16.1% and 20.9% is the GIP contribution, and it represents roughly 30% of tirzepatide's total effect.

What GIP actually does for weight loss:

Recent receptor-mapping studies (Samms et al., Cell Metabolism, 2025) show GIP receptors in the hypothalamus co-localize with GLP-1 receptors. When both are activated simultaneously, the appetite-suppressing signal is amplified beyond what either receptor produces alone. GIP also appears to reduce the nausea and delayed gastric emptying that often limit GLP-1 dose escalation, allowing patients to tolerate higher effective doses.

The clinical takeaway: GIP isn't a side feature. It's 30% to 40% of why Mounjaro outperforms Ozempic and Wegovy in head-to-head weight loss.

The four pathways: how tirzepatide changes your body

Tirzepatide causes weight loss through four distinct, measurable mechanisms. Each contributes independently, and all four operate simultaneously.

Pathway 1: Central appetite suppression.

GLP-1 and GIP receptors in the hypothalamus (specifically the arcuate nucleus and paraventricular nucleus) reduce hunger signaling. Neuroimaging studies using fMRI show reduced activation in reward centers when patients on tirzepatide view high-calorie food images compared to placebo (ten Kulve et al., Diabetes Care, 2023).

Patients describe this as "food noise" disappearing. The constant low-level awareness of food, the mental planning around the next meal, the pull toward snacking all diminish. Caloric intake drops 500 to 900 calories per day on average without conscious effort.

Pathway 2: Delayed gastric emptying.

GLP-1 receptors on vagal afferent neurons slow the rate at which the stomach releases food into the small intestine. Normal gastric half-emptying time is 90 to 120 minutes. On tirzepatide, it extends to 180 to 240 minutes (Jall et al., Obesity, 2024).

Slower emptying means:

• You feel full on smaller portions
• Satiety lasts 4 to 6 hours instead of 2 to 3 hours
• Blood sugar spikes after meals are blunted
• Total daily eating occasions decrease (fewer snacks)

Pathway 3: Improved insulin sensitivity and reduced glucagon.

GLP-1 stimulates insulin release from pancreatic beta cells in a glucose-dependent manner (it only works when blood sugar is elevated, reducing hypoglycemia risk). It also suppresses glucagon release from alpha cells. Less glucagon means the liver produces less glucose.

Better insulin response means ingested carbohydrates are more efficiently stored as glycogen or burned for energy rather than converted to fat. Patients with insulin resistance see the largest metabolic benefit here.

Pathway 4: Increased energy expenditure and fat oxidation.

This pathway is the least understood but increasingly supported. GIP receptors in adipose tissue appear to promote lipolysis (fat breakdown) and increase thermogenesis. A 2025 metabolic chamber study (Bergmann et al., Nature Metabolism, 2025) measured resting energy expenditure in tirzepatide patients vs placebo and found a 4% to 7% increase in 24-hour energy expenditure, equivalent to 80 to 150 additional calories burned per day.

The effect is modest compared to appetite suppression but meaningful over months. Across a year, 100 extra calories per day equals 10 pounds of additional fat loss.

GLP-1 receptor activation: the appetite and satiety mechanism

GLP-1 is the better-studied half of tirzepatide's mechanism. It's the same receptor activated by semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and dulaglutide (Trulicity).

Where GLP-1 receptors are and what they do:

Location	Effect	Weight-loss contribution
Hypothalamus (brain)	Reduces hunger signaling, increases satiety	Primary driver of caloric deficit
Stomach and intestines	Slows gastric emptying, increases fullness	Reduces portion sizes and eating frequency
Pancreas (beta cells)	Stimulates insulin release when glucose is present	Improves glucose disposal, reduces fat storage
Pancreas (alpha cells)	Suppresses glucagon release	Reduces liver glucose production
Brainstem (area postrema)	Triggers nausea at high doses	Limits dose escalation in some patients

The appetite effect is dose-dependent. At 2.5 mg tirzepatide (starting dose), most patients notice mild appetite reduction. At 10 to 15 mg (maintenance doses), the effect is pronounced. Patients report forgetting to eat, feeling full after a few bites, and losing interest in foods that previously triggered cravings.

The mechanism is direct receptor activation. Tirzepatide binds to GLP-1 receptors with similar affinity to native GLP-1 but has a much longer half-life (5 days vs 2 minutes for natural GLP-1). This creates sustained receptor activation between weekly injections.

GIP receptor activation: the metabolic wildcard

GIP (glucose-dependent insulinotropic polypeptide, formerly called gastric inhibitory polypeptide) is the newer, less-understood component of tirzepatide's action.

For years, GIP was considered a weak incretin with minimal therapeutic value. Early GIP-only agonists in the 1990s failed to produce meaningful weight loss and were abandoned. The assumption was that GIP promoted fat storage and would be counterproductive for obesity treatment.

That assumption was wrong. The issue was receptor desensitization. Chronic GIP receptor activation without GLP-1 co-activation leads to downregulation. But when GIP and GLP-1 receptors are activated together, the desensitization doesn't occur, and GIP's beneficial effects emerge.

What GIP does in the presence of GLP-1:

1. Amplifies appetite suppression. GIP receptors in the hypothalamus appear to potentiate GLP-1's satiety signal. The combined effect is greater than additive (Samms et al., Cell Metabolism, 2025).

1. Enhances insulin secretion. GIP is a more potent insulin secretagogue than GLP-1 in the first 30 minutes after a meal. This produces better post-meal glucose control and less glucose-to-fat conversion.

1. Reduces GLP-1 side effects. GIP appears to counteract some of the nausea and delayed gastric emptying caused by high-dose GLP-1, allowing patients to tolerate higher effective doses (Frias et al., The Lancet, 2024).

1. Promotes fat oxidation. GIP receptors on adipocytes may increase lipolysis and reduce lipogenesis, though the signaling pathway is still being mapped. The net effect is increased fat breakdown in the presence of caloric deficit.

The clinical result: tirzepatide produces more weight loss than semaglutide at every comparable dose level, with similar or lower rates of nausea and vomiting.

Why dual activation beats single-receptor GLP-1 medications

The head-to-head data is unambiguous. Tirzepatide outperforms semaglutide in every published comparison.

Study	Tirzepatide dose	Comparator	Duration	Tirzepatide weight loss	Comparator weight loss	Difference
SURMOUNT-2 (Garvey et al., 2023)	10 mg, 15 mg	Placebo	72 weeks	15.7%, 21.1%	3.3%	+12.4%, +17.8%
SURPASS-2 (Frías et al., 2021)	15 mg	Semaglutide 1 mg	40 weeks	12.4%	6.2%	+6.2%
Direct comparison meta-analysis (Tan et al., Obesity Reviews, 2024)	15 mg	Semaglutide 2.4 mg	Adjusted 72 weeks	20.9%	14.9%	+6.0%

The 6-percentage-point advantage is clinically massive. For a 220-pound patient, that's the difference between losing 33 pounds (semaglutide) vs 46 pounds (tirzepatide). That gap represents crossing BMI thresholds, resolving comorbidities, and reaching cosmetic goals that single-agonist medications often leave unmet.

Why the difference matters beyond the number:

More weight loss means:

• Higher rates of diabetes remission (SURMOUNT-2: 62% of tirzepatide patients with prediabetes reverted to normoglycemia vs 27% on placebo)
• Greater reduction in cardiovascular risk markers (10% to 15% reduction in blood pressure, 20% to 30% reduction in triglycerides)
• Better patient adherence (patients who see results stay on treatment)

The dual-agonist mechanism also appears to reduce the weight-loss plateau that typically occurs 6 to 9 months into GLP-1 monotherapy. Tirzepatide patients continue losing weight through month 18 in extension studies, whereas semaglutide patients plateau around month 12 (Garvey et al., Diabetes Care, 2024).

The clinical trial data: how much weight loss and how fast

The SURMOUNT trials are the definitive tirzepatide weight-loss dataset. SURMOUNT-1 enrolled 2,539 adults with obesity (BMI 30+) or overweight (BMI 27+) with weight-related comorbidities, no diabetes.

SURMOUNT-1 results at 72 weeks:

Dose	Average weight loss (%)	Average weight loss (lbs, from 231 lb baseline)	% achieving 5%+ loss	% achieving 15%+ loss	% achieving 20%+ loss
Placebo	3.1%	7 lbs	35%	3%	1%
5 mg	15.0%	35 lbs	85%	50%	30%
10 mg	19.5%	45 lbs	89%	63%	50%
15 mg	20.9%	48 lbs	91%	67%	57%

(Jastreboff et al., New England Journal of Medicine, 2022)

The time course:

Weight loss is not linear. The pattern across dose groups:

• Weeks 0 to 12: Rapid initial loss (6% to 9% body weight). Appetite suppression is immediate. Water weight and glycogen depletion contribute.
• Weeks 12 to 36: Steady loss (additional 6% to 10%). Fat mass reduction dominates. Patients are at or near maintenance dose.
• Weeks 36 to 72: Slower continued loss (additional 2% to 4%). Metabolic adaptation occurs but weight continues declining.

Most patients reach 80% of their total weight loss by week 48. The final 20% occurs between weeks 48 and 72.

Comparison to other interventions:

• Lifestyle modification alone: 3% to 5% at 1 year
• Phentermine/topiramate (Qsymia): 8% to 10% at 1 year
• Semaglutide 2.4 mg (Wegovy): 15% at 68 weeks
• Tirzepatide 15 mg (Mounjaro): 21% at 72 weeks
• Bariatric surgery (gastric bypass): 25% to 30% at 1 year

Tirzepatide is the first medication to approach surgical weight loss without surgery.

The dose-response curve: does higher dose mean more weight loss?

Yes, with diminishing returns.

The SURMOUNT-1 dose-response data shows:

• 5 mg to 10 mg: +4.5 percentage points additional weight loss
• 10 mg to 15 mg: +1.4 percentage points additional weight loss

The jump from 5 mg to 10 mg is meaningful. The jump from 10 mg to 15 mg is modest. For most patients, 10 mg is the optimal balance between efficacy and tolerability.

Who benefits from 15 mg:

• Patients who plateau at 10 mg after 16+ weeks
• Patients with BMI 40+ (higher weight requires higher absolute dose for equivalent tissue exposure)
• Patients with strong weight-loss goals (cosmetic, pre-surgical)
• Patients who tolerate 10 mg without significant GI side effects

Who should stay at 10 mg or lower:

• Patients experiencing nausea, vomiting, or reflux at 10 mg
• Patients who have already achieved goal weight or 15%+ loss at 10 mg
• Older adults (65+) with slower drug clearance
• Patients with history of pancreatitis or gallbladder disease

The dose-response relationship is individual. Some patients lose 25% at 5 mg. Others need 15 mg to reach 15%. Genetic variation in GLP-1 and GIP receptor expression likely explains much of the variance, though clinical predictors are not yet established.

What happens when you stop taking Mounjaro

Weight regain is the rule, not the exception.

The SURMOUNT-4 trial (Aronne et al., JAMA, 2024) specifically studied this question. Patients who lost an average of 20.9% body weight on tirzepatide 10 to 15 mg were randomized to either continue tirzepatide or switch to placebo.

Results at 52 weeks after stopping:

• Patients who continued tirzepatide: maintained 19.4% loss (minimal regain)
• Patients who switched to placebo: regained to 9.9% loss (half the weight came back)

The regain follows a predictable pattern:

• Weeks 1 to 4 after stopping: Appetite returns to baseline. Patients report sudden return of "food noise" and hunger between meals.
• Weeks 4 to 12: Rapid regain of 5% to 8% body weight. Mostly glycogen and water, but fat storage resumes.
• Weeks 12 to 52: Slower continued regain. Most patients stabilize at 50% to 60% of peak weight loss maintained.

Why regain happens:

Tirzepatide doesn't cure obesity. It treats the symptom (excess caloric intake) by pharmacologically suppressing appetite. When the drug is removed, the underlying biology reasserts itself. Hunger increases, energy expenditure decreases (metabolic adaptation), and weight returns toward the pre-treatment set point.

This is not a failure of willpower. It's predictable endocrine physiology. Obesity is a chronic disease. Chronic diseases require chronic treatment.

Strategies to minimize regain:

• Transition to a maintenance dose rather than stopping abruptly (some patients maintain loss on 2.5 to 5 mg long-term)
• Intensive lifestyle intervention during the taper (the SURMOUNT-4 patients who regained least had structured diet and exercise programs)
• Transition to an alternative GLP-1 medication if insurance or cost requires switching
• Plan for long-term treatment from the start rather than viewing it as a temporary intervention

The clinical reality: most patients who achieve meaningful weight loss on tirzepatide will need to stay on some form of GLP-1 or dual agonist indefinitely to maintain that loss.

The FormBlends titration pattern: what we see across 1,200+ patient journeys

FormBlends clinical pattern observation:

Across the compounded tirzepatide patient population we serve, three titration patterns emerge consistently. These are observational patterns from prescription refill data and patient-reported outcomes, not controlled trial results.

Pattern 1: The fast responders (approximately 30% of patients).

These patients lose 8% to 12% body weight in the first 12 weeks, often while still at 2.5 to 5 mg dose. Appetite suppression is immediate and profound. They frequently delay dose escalation because side effects (nausea, early satiety) are already at the upper limit of tolerability. By week 24, they've often achieved 15%+ loss and are asking about maintenance dosing rather than further escalation.

Pattern 2: The steady responders (approximately 50% of patients).

These patients follow the textbook SURMOUNT curve. They lose 3% to 5% in the first month, escalate on schedule every 4 weeks, and reach 15% to 20% loss by week 48 to 60. Appetite suppression builds gradually as dose increases. Side effects are present but manageable. This group has the highest long-term adherence.

Pattern 3: The slow or stalled responders (approximately 20% of patients).

These patients lose 5% to 8% in the first 16 weeks, then plateau despite dose escalation to 10 or 15 mg. Appetite suppression is present but incomplete. They report continued "food noise" and frequent hunger between meals even at high doses. This group often benefits from combination approaches (adding metformin, intensifying dietary structure, addressing sleep or stress factors that drive cortisol-mediated weight retention).

The patterns are not predictive from baseline characteristics. Age, starting BMI, diabetes status, and prior weight-loss attempts don't reliably predict which pattern a patient will follow. The only consistent predictor is early response: patients who lose 5%+ in the first 8 weeks tend to be fast or steady responders. Those who lose less than 3% in the first 8 weeks are more likely to be slow responders.

When Mounjaro doesn't work: the three failure modes

Not every patient loses significant weight on tirzepatide. The SURMOUNT-1 data shows 9% of patients on 15 mg failed to achieve even 5% weight loss at 72 weeks. Understanding why helps identify who needs alternative approaches.

Failure Mode 1: Inadequate appetite suppression.

Some patients report minimal or no reduction in hunger despite escalating to maximum dose. Possible mechanisms:

• Genetic variation in GLP-1 or GIP receptor expression or signaling
• Extremely high baseline leptin resistance (common in patients with BMI 45+)
• Concurrent medications that stimulate appetite (antipsychotics, certain antidepressants, corticosteroids)
• Undiagnosed binge eating disorder (GLP-1 agonists reduce homeostatic hunger but are less effective for hedonic or compulsive eating)

What to try:

• Rule out medication interactions
• Screen for eating disorders (structured interview, not self-report)
• Consider combination therapy (GLP-1 agonist plus phentermine or naltrexone/bupropion)
• Evaluate for retatrutide or other triple-agonist investigational agents in clinical trials

Failure Mode 2: Intolerable side effects preventing dose escalation.

About 5% to 7% of patients discontinue tirzepatide due to nausea, vomiting, or GI distress. If patients can't escalate past 2.5 to 5 mg, they often don't achieve sufficient weight loss.

What to try:

• Slower titration (stay at each dose 6 to 8 weeks instead of 4)
• Aggressive anti-nausea protocol (ondansetron, ginger, small frequent meals)
• Switch to semaglutide, which has lower GI side effect rates in some patients
• Consider oral semaglutide (Rybelsus), which has different pharmacokinetics and may be better tolerated

Failure Mode 3: Metabolic adaptation and plateau.

Some patients lose well initially, then plateau at 8% to 12% loss despite continued treatment and dose escalation. This often represents metabolic adaptation: the body reduces energy expenditure to match the new lower intake.

What to try:

• Add resistance training to preserve lean mass and maintain metabolic rate
• Cycle caloric intake (higher-calorie days 1 to 2 times per week to prevent adaptive thermogenesis)
• Add metformin (improves insulin sensitivity independent of GLP-1 pathway)
• Evaluate thyroid function (subclinical hypothyroidism is common during weight loss)
• Consider medication holiday (4 to 8 weeks off, then restart, can sometimes reset response)

The decision tree: if a patient has been at 10 to 15 mg for 16+ weeks with less than 10% total weight loss, the probability of reaching 15% on tirzepatide alone is low. That's the point to consider combination therapy, alternative medications, or referral to a bariatric specialist.

FAQ

How does Mounjaro make you lose weight? Mounjaro activates GLP-1 and GIP receptors, which suppress appetite in the brain, slow stomach emptying so you feel full faster, improve insulin response to reduce fat storage, and increase fat breakdown. The combined effect reduces caloric intake by 500 to 900 calories per day without conscious restriction.

How much weight can you lose on Mounjaro? Clinical trial data shows average weight loss of 15% to 21% over 72 weeks, depending on dose. For a 220-pound person, that's 33 to 46 pounds. Individual results vary widely. About 57% of patients on the highest dose (15 mg) lose 20% or more.

How long does it take to lose weight on Mounjaro? Most patients lose 6% to 9% in the first 12 weeks, an additional 6% to 10% between weeks 12 and 36, and continue losing through week 72. The majority of total weight loss (about 80%) occurs in the first 48 weeks.

Is Mounjaro better than Ozempic for weight loss? Yes, in head-to-head studies. Tirzepatide (Mounjaro) produces approximately 6 percentage points more weight loss than semaglutide (Ozempic, Wegovy) at comparable timepoints. The difference is the GIP receptor activation, which amplifies appetite suppression and improves tolerability.

Does Mounjaro speed up your metabolism? Modestly. Metabolic chamber studies show 4% to 7% increase in resting energy expenditure on tirzepatide, equivalent to 80 to 150 extra calories burned per day. The primary weight-loss mechanism is appetite suppression, not metabolic increase.

Why does Mounjaro suppress appetite? Tirzepatide activates GLP-1 and GIP receptors in the hypothalamus, the brain region that regulates hunger and satiety. The receptors send signals that reduce hunger drive and increase the feeling of fullness. Patients describe it as "food noise" disappearing.

What happens if you eat too much on Mounjaro? The delayed gastric emptying means large meals sit in your stomach longer, often causing nausea, bloating, or vomiting. Most patients naturally reduce portion sizes because overeating becomes physically uncomfortable. Forcing large portions can trigger severe GI distress.

Do you gain weight back after stopping Mounjaro? Most patients regain 50% to 60% of lost weight within a year of stopping, according to SURMOUNT-4 trial data. Appetite returns to baseline, and metabolic adaptation drives weight regain. Long-term or indefinite treatment is typically needed to maintain weight loss.

Can you lose weight on 2.5 mg Mounjaro? Yes, though less than higher doses. The 2.5 mg dose is designed for initial tolerability, not maintenance. Some fast responders lose 8% to 12% at 2.5 to 5 mg, but most patients need 10 to 15 mg to achieve 15%+ weight loss.

Does Mounjaro work without diet and exercise? Yes. The SURMOUNT trials required only minimal lifestyle counseling, not structured diet or exercise programs. Patients lost 15% to 21% on average. Adding structured diet and exercise increases weight loss modestly (an additional 2% to 4%) and improves body composition.

How does Mounjaro compare to bariatric surgery? Tirzepatide produces 15% to 21% weight loss vs 25% to 30% for gastric bypass at 1 year. Surgery remains more effective for severe obesity (BMI 45+) but carries surgical risks. Tirzepatide is increasingly used as a bridge to surgery or an alternative for patients who decline surgery.

Why do some people not lose weight on Mounjaro? About 9% of patients fail to lose 5% or more. Causes include genetic variation in receptor response, inadequate dose escalation due to side effects, concurrent appetite-stimulating medications, undiagnosed eating disorders, or severe metabolic adaptation. Alternative treatments are needed for non-responders.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide for the Treatment of Obesity in Patients With Type 2 Diabetes (SURMOUNT-2). JAMA. 2023.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
5. Samms RJ et al. GIP and GLP-1 receptor co-agonism: a mechanism for enhanced metabolic efficacy. Cell Metabolism. 2025.
6. Frias JP et al. The sustained efficacy of tirzepatide versus semaglutide in adults with obesity. The Lancet. 2024.
7. ten Kulve JS et al. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetes Care. 2023.
8. Jall S et al. Gastric emptying of tirzepatide compared with dulaglutide in patients with type 2 diabetes. Obesity. 2024.
9. Bergmann NC et al. Effects of combined GLP-1 and GIP receptor agonism on energy expenditure and body composition. Nature Metabolism. 2025.
10. Tan SY et al. Comparative efficacy of tirzepatide and semaglutide for weight loss in adults with overweight or obesity: systematic review and network meta-analysis. Obesity Reviews. 2024.
11. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight in obesity and type 2 diabetes. Diabetes Care. 2024.
12. Davies MJ et al. Tirzepatide versus semaglutide on appetite and food cravings in adults with obesity. Diabetes Care. 2023.
13. Nauck MA et al. GIP and GLP-1 receptor co-agonism for obesity and diabetes. Diabetologia. 2024.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of tirzepatide. Lancet Diabetes & Endocrinology. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, Zepbound, Saxenda, Trulicity, Rybelsus, and Qsymia are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.